Across TCGA pan-cancer cohorts, IGLJ5 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IGLJ5 data layer compared with 8 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher IGLJ5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGLJ5 expression acts as an unfavorable survival marker.

OV are the cancer types where IGLJ5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.082	0.844	<.001	36	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: IGLJ5 tumor-vs-normal RNA expression · all IGLJ5 data types